Novo Nordisk Ranked Among the Top 25 Best Multinational Workplaces

Nov 14, 2012 9:15 AM ET
Press Release

Bagsværd, Denmark, November 14, 2012 /3BL Media/ - Novo Nordisk has for the second year in a row just been ranked among the top 25 best multinational workplaces, according to the Great Place to Work® Institute. Just as last year, Novo Nordisk is ranked 22nd.

The 25 companies were selected from a total of 350 multinational companies from 45 countries that participated in the selection process for the best multinational workplaces.

The ranking is determined by company employees. Qualifying companies must have appeared on at least five national Great Place to Work® lists, have at least 5,000 employees worldwide, and at least 40% of their global workforce must work outside of the company’s home country.

“We're honoured to receive this recognition from Great Place to Work®. As a global company with more than 33,000 employees in 75 countries, we work hard to ensure a unified and thriving culture. Our employees are among the best in the industry and their passion and commitment is the reason our company is a world leader in diabetes care,” says Lars Christian Lassen, senior vice president with global responsibility for human resources in Novo Nordisk.

Earlier this year, Novo Nordisk was ranked number 43 on Fortune’s 100 Best Companies to Work For and the fourth best scientific employer on Science Magazine’s Top Employers Survey.

About Great Place to Work

Great Place to Work® Institute, Inc. is a global research, consulting and training firm that helps organisations identify, create and sustain great workplaces through the development of high-trust workplace cultures. Great Place to Work® serves businesses, non-profit organisations and government agencies in 45 countries on six continents.

Link to Great Place to Work:

Headquartered in Denmark, Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. For more information, visit

Further information




Katrine Sperling

+45 4442 6718

Ken Inchausti (US)

+1 609 514 8316